目的探讨利培酮对儿童期首发精神分裂症的临床疗效和安全性。方法对60例年龄<14岁首次发病患儿用利培酮治疗8周,以阳性和阴性症状量表(PANSS)评定临床疗效;以副反应量表(TESS)和实验室监测评价安全性;于基线时,实验第1、2、4、6、8周末分别评定各量表。统计方法为描述性分析和配对t检验。结果60例患儿基本痊愈20.0%(12/60),显著进步30.0%(18/60),好转30.0%(18/60)和无效20.0%(12/60)。PANSS总分及各分量表分治疗前后比较均有显著性差异(P<0.01),利培酮对阳性、阴性症状以及一般精神病性症状均有良好疗效。无严重不良反应。结论利培酮能缓解儿童期首发精神分裂症的精神病性症状,疗效好,安全性高。 Objective To investigate the clinical efficacy and safety of risperidone in first-episode schizophrenia in childhood. Methods Sixty first-episode children aged <14 years were treated with risperidone for 8 weeks, and the clinical efficacy was assessed by Positive and Negative Syndrome Scale (PANSS). Safety was assessed by TESS and laboratory monitoring. At baseline, the scales were evaluated on the 1st, 2nd, 4th, 6th and 8th week of the experiment respectively. Statistical methods were descriptive analysis and paired t-test. Results 60 cases were basically cured 20.0% (12/60), a significant improvement of 30.0% (18/60), improvement of 30.0% (18/60) and ineffective 20% (12/60). PANSS scores and subscales were significantly different before and after treatment (P <0.01), and risperidone had good effect on positive and negative symptoms as well as general psychotic symptoms. No serious adverse reactions. Conclusions Risperidone can relieve the psychiatric symptoms of schizophrenia in childhood, with good curative effect and high safety.